IVC filter design and development
Surgical interruption of the inferior vena cava (IVC) to prevent pulmonary embolus (PE) was first performed in 1893. Unsurprisingly, this did not gain widespread acceptance. In 1959, a surgically placed external clip was used to reduce the IVC to a slit. The first transvenous IVC filter, the Mobin-Uddin filter, was introduced in 1967. Transvenous devices were attractive as although a surgical femoral vein cutdown and a large sheath (24F) were required, no laparotomy or general anaesthetic was necessary. The Mobin-Uddin filter quickly fell out of favour due to the high incidence of IVC occlusion. It was soon followed by the stainless steel, Kimray-Greenfield filter that was used and refined over subsequent years.
Despite the lack of evidence for their use and growing awareness of complications, IVC filters became widely used. There have been several generations of IVC filters as designs have evolved and been refined. Designers initially focused on effectiveness of clot filtration and reducing the size of the delivery system (now typically 9F allowing true percutaneous insertion). Subsequent focus has been on reducing complications such as migration and caval perforation.
About 10 years ago permanent/retrievable IVC filters became available. These could be removed percutaneously, when no longer required, or could be left in permanently (although the long-term safety profile of these devices was unknown). The technical success rate of IVC filter retrieval is high, (even with tilting and caval perforation) although decreases with time from insertion (over 90% at three months to less than 40% at 12 months). These permanent/retrievable devices currently account for the majority of IVC filters inserted. However, it has become apparent that there are significant issues with these devices with low retrieval rates and complications. A quick trawl of the internet reveals multiple legal actions being brought against IVC filter manufacturers in the USA.
The current generation of filters have features to prevent caval perforation (and hence tilting, which reduces filtration efficiency and can make retrieval impossible) and migration. Most are based on the metal alloy 'wire' cone shape (eg Bard -Denali - Figure 1 ) while others are a very different design (Crux Biomedical -Crux). Some manufacturers are exploring bioconvertible/bioabsorbable filters that resorb over time (eg the Novate Medical filter is a filter within a stent, the filter resorbs after 60 days leaving a stent which is incorporated into the caval wall). Other manufacturers have explored devices that can be placed at the bedside without radiological guidance (using either intravascular ultrasound or by judging implant level from the patient' s heightthe Angel ® Catheter (BiO 2 Medical) -where a filter is combined with a central line).
Efficacy and indications
For such a widely used device there is an astonishing lack of evidence of efficacy, 1 with only two small randomised studies of limited usefulness. The PREPIC study of 400 anticoagulated patients randomised to receive IVC filter, or no IVC filter demonstrated a significant reduction in the incidence of PE (to approximately half) but no reduction in mortality, either short-or long-term (possibly reflecting the old age of the patients with the majority of deaths due to cancer or cardiovascular disease). 2, 3 The PREPIC study has been influential but has been criticised for being underpowered and biased. The second randomised study of
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Complications
Although popular and widely accepted, IVC filters have come under renewed scrutiny with the growing awareness of complications. 9 These include, failure to protect from PE, IVC occlusion, filter fragmentation and embolisation of fragments to the heart and lungs and caval perforation into adjacent structures (many have been described including the aorta and duodenum) ( Table 2 ). Attempted retrieval of IVC filters also has complications and fatalities have been reported. In addition to these problems it has become apparent that many (often the majority) of retrievable IVC filters are not being retrieved. The reason for this is multifactorial -including loss to follow-up, no formal system for arranging retrieval and the perception that IVC filters are harmless. This has led to warnings and new instructions from both the FDA and MHRA. Dedicated longitudinal follow-up programmes with formal arrangements for filter retrieval and early filter removal (as soon as the filter is no longer necessary) are advised.
The risk of deep venous thrombosis (DVT) doubles with the presence of an IVC filter. IVC thrombosis can occur and is associated with increased risk of PE, post thrombotic syndrome and phlegmasia cerulea dolens (blue oedema). For this reason patients with IVC filters should be anticoagulated as soon as the contraindication to anticoagulation resolves. Special care should be taken when inserting a central venous catheter in a patient with an IVC filter as the guide wire can become caught in the filter and impossible to remove or may displace the filter.
Conclusion
IVC filters have been in use for more than 45 years and yet for such a widely used device, we have little data on their efficacy or indications for use. However, most practitioners advocate their use in acute PE or proximal DVT with an absolute contra-indication to anticoagulation. We have better data on their complications and although the risk of serious complications is relatively low, these cannot be ignored and there have been recent warnings from the FDA and MHRH. One large area of concern is the widespread nonretrieval of retrievable filters for a variety of reasons and measures to address this have been advised. Patients with IVC filters should be anticoagulated when safe to do so and temporary filters should be removed as soon as possible (usually when anticoagulation is effective).
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